Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Classical hematology 1

Conditions

Anemia 3Anemia, Iron-Deficiency 2Plexosarcoma 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Gastrointestinal Stromal Tumors 1

Interventions

Epoetin Alfa 25Darbepoetin alfa 17apixaban 9Rivaroxaban 9Dalteparin 7Heparin, Low-Molecular-Weight 6Surveys and Questionnaires 5Meropenem 5fludarabine phosphate 4Vancomycin 4Tinzaparin 4Enoxaparin 4Cyclosporine 4Cefepime 4ferric carboxymaltose 3edoxaban 3Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Ceftazidime 3Carboplatin 3Busulfan 3Antilymphocyte Serum 3Amikacin 3romiplostim 2peginesatide 2hematide 2fludarabine 2epoetin beta 2bemiparin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Iron-Dextran Complex × Classical hematology × Clear all
NCT00401544 2014-01-29

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Amgen

Phase 2 Completed
243 enrolled 26 charts
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡